Cencora Directors Reach $111 Million Deal on Opioid Claims

Aug. 15, 2025, 8:48 PM UTC

Cencora Inc. directors have agreed to a settlement of more than $111 million to resolve claims by pension funds that they ignored years of red flags about the drug distributor’s handling of opioid painkillers and failed to set up required systems to monitor sales of the drugs.

The deal would end litigation accusing directors of turning a blind eye to suspiciously large opioid shipments to reap billions for the firm, which was known until 2023 as AmerisourceBergen Corp. before it changed its name.

The settlement disclosed Friday in a filing in Delaware Chancery Court comes after the company has paid ...

Learn more about Bloomberg Law or Log In to keep reading:

See Breaking News in Context

Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.

Already a subscriber?

Log in to keep reading or access research tools and resources.